Newsroom Bayer

May
25,
2023
| 13:59 PM Europe/Amsterdam
Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223
May
23,
2023
| 19:07 PM Europe/Amsterdam

Bayer issues new senior bonds with a volume of 3 billion euros

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Issuance consisted of three tranches with maturities between 3.25 and 10 years and was substantially oversubscribed
May
17,
2023
| 13:59 PM Europe/Amsterdam
Chinese National Medical Products Administration granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase
May
16,
2023
| 13:11 PM Europe/Amsterdam
Funding advances BBI-355, a potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor, through meaningful clinical data readouts in Phase 1/2 POTENTIATE clinical trial
May
16,
2023
| 08:29 AM Europe/Amsterdam
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries / Asundexian is being evaluated as a potential improved treatment option in
May
11,
2023
| 07:29 AM Europe/Amsterdam

Slow start to the year as expected

Bayer Group business performance in the first quarter of 2023:

Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o   Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso   New Pharmaceuticals products deliver strong growth –
May
11,
2023
| 07:29 AM Europe/Amsterdam
Four oral presentations and seven poster presentations will share insights into AskBio’s adeno-associated virus research, development and pre-clinical product progress / Breadth of research reinforces AskBio’s continued commitment to the development
May
10,
2023
| 12:59 PM Europe/Amsterdam
Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology / Advancing the use of bicycle peptides as a novel targeting approach in
May
10,
2023
| 09:59 AM Europe/Amsterdam
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related
May
09,
2023
| 08:59 AM Europe/Amsterdam

Bayer to present latest research on treatment of vasomotor symptoms in women with breast cancer receiving endocrine adjuvant therapy at ESMO Breast Cancer 2023

Not intended for U.S. and UK Media - Annual Congress of European Society For Medical Oncology Breast Cancer 2023:

Poster presentation from the REALISE study, a real-world evidence analysis evaluating the status of treatment of vasomotor symptoms (VMS) and symptom burden in women taking adjuvant endocrine therapy (AET) after breast cancer, showing a need for new
May
04,
2023
| 22:15 PM Europe/Amsterdam
Global Bayer Co.Lab network of life science incubators established to accelerate innovation and foster collaborations within vibrant biotech ecosystems / U.S. flagship location opening in Cambridge, MA, encompasses state-of-the-art laboratories and

Sign up for our Newsletter

We will keep you informed about the latest news.